NEW YORK, March 1, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Celgene Corporation ("Celgene" or the "Company") (NASDAQ: CELG). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/celg.
The investigation concerns whether Celgene and certain of its officers and/or directors have violated federal securities laws.
On February 27, 2018, post-market, Celgene disclosed that the U.S. Food and Drug Administration ("FDA") had rejected the Company's New Drug Application ("NDA") for Ozanimod, a multiple sclerosis treatment. Celgene stated that it had received a refusal-to-file letter from the FDA, which advised the Company that it had "determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review." On this news, Celgene's share price fell $8.66, or 9.04%, to close at $87.12 on February 28, 2018.
If you are aware of any facts relating to this investigation, or purchased Celgene shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/celg. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-celgene-corporation-celg-300606579.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Share this article